Cancer's ability to hide in dormant states represents one of oncology's most vexing challenges, enabling tumor cells to evade treatment and resurface years later as aggressive metastases. This breakthrough in precision cancer therapeutics demonstrates how engineered molecules can use light to selectively target these sleeping malignant cells without disrupting healthy tissue function. The research centers on glucocorticoid receptors, stress hormone pathways that cancer cells hijack to enter protective dormancy states when threatened by chemotherapy or radiation. While blocking these receptors system-wide would be toxic, the new photoswitchable degrader compounds remain inactive until exposed to specific wavelengths of light. This optical control allows clinicians to activate the cancer-disrupting effect only in illuminated tissue areas, potentially through fiber optic delivery during surgical procedures or targeted light therapy sessions. The molecules work by selectively degrading glucocorticoid receptors in cancer cells, forcing dormant tumors out of their protective hibernation and back into vulnerable, actively dividing states where conventional treatments can eliminate them. This represents a fundamentally new approach to cancer dormancy, one of the field's most persistent obstacles. Rather than trying to kill sleeping cancer cells directly, the strategy awakens them in controlled circumstances where they become susceptible to existing therapies. The precision targeting addresses a critical limitation that has prevented effective dormancy disruption - the need to avoid interfering with glucocorticoid signaling in healthy tissues where these stress hormones regulate essential functions like immune response and metabolism. While promising, the approach requires validation in complex tumor environments and careful assessment of light penetration limitations in deep tissues.